A team from the University of Ottawa’s Faculty of Medicine has completed an exciting new study that reveals the inner workings of gene mutations that result in an ultra-rare syndrome with fewer than 100 reported cases since its first description in the early 1960s.
DOJ subpoenas BioMarin over sponsored testing program for rare disease drugs
The Department of Justice has issued a subpoena to BioMarin over issues with its sponsored testing programs for two of its rare disease drugs, the